
1995

- CCSS had 0 publication
- Internet access by Dial-up
- Amazon.com sold its 1st book online
- I was a new PhD & got the great opportunity to work with CCSS founders



2001

- CCSS had published 5 papers
- Amazon.com turned its first profit

Norm **Breslow**

A CCSS founder who, with John Potter, recruited me to work on CCSS in **1995**

"He really did lay the foundation for <u>all modern</u> <u>statistical methods in epidemiology and public health</u>," said Ron Brookmeyer, a UCLA biostatistics professor.








Second Malignant Neoplasms in Five-Year Survivors of Childhood Cancer: Childhood Cancer Survivor Study

Joseph P. Neglia, Debra L. Friedman, Yutaka Yasui, Ann C. Mertens, Sue Hammond, Marilyn Stovall, Sarah S. Donaldson, Anna T. Meadows, Leslie L. Robison



If I am the reviewer, I would reject this paper.





Working Group => Gate of entry to CCSS

PLEASE CONTACT ME IF YOU HAVE <u>ANY INTEREST OR IDEA</u> ON POTENTIAL EPI/BIOSTAT PROJECTS

Yutaka.Yasui@stjude.org



Epidemiology/Biostatistics Working Group Report

CCSS Investigators Meeting June, 2017



- 1. Scope of your Working Group
- 2. Publications since the 2015 mtg
- 3. Ongoing work
- 4. Future focus



1. Scope of your Working Group

2. Publications since the 2015 mtg

- 3. Ongoing work
- 4. Future focus



- Methodological and "other" studies
- Analysis of CCSS mortality data
- Integrity/innovation of popultionscience methodology (with Wendy, Ann, Les, ...), working with other WGs



1. Scope of your Working Group

2. Publications since the 2015 mtg

3. Ongoing work

4. Future focus



Publications 264

The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE

Reduction in Late Mortality among 5-Year Survivors of Childhood Cancer

Gregory T. Armstrong, M.D., M.S.C.E., Yan Chen, M.M., Yutaka Yasui, Ph.D.,
Wendy Leisenring, Sc.D., Todd M. Gibson, Ph.D., Ann C. Mertens, Ph.D.,
Marilyn Stovall, Ph.D., Kevin C. Oeffinger, M.D., Smita Bhatia, M.D., M.P.H.,
Kevin R. Krull, Ph.D., Paul C. Nathan, M.D., Joseph P. Neglia, M.D., M.P.H.,
Daniel M. Green, M.D., Melissa M. Hudson, M.D., and Leslie L. Robison, Ph.D.

ASSOCIATED PRESENTATION




Meeting: 2015 ASCO Annual Meeting Presenter: Gregory T. Armstrong

View Video




A Death from Any Cause



1970s	9,416	8,722	8,406	8,182	7942	5556	1506
1980s	13,181	13,443	13,105	10,389	3583		
1990s	11,436	11,411	3,924				




B Death from Recurrence or Progression





C Death from Health-Related Cause



	2,110	0,122	0,100	0,102	1212	
1980s	13,181	13,443	13,105	10,389	3583	
1990s	11,436	11,411	3,924			





- Temporal trends papers (Armstrong *et al.* NEJM 2016, Turcotte *et al.* JAMA 2017, Ness *et al.* Ann Intern Med 2017)
- Show trends in the outcome of interest
- Show trends in relevant treatment
- "Is it really the therapy changes that led to the outcome changes?"




B

Hodgkin's Lymphoma











Acute Lymphoblastic Leukemia

Relative rate of mortality 0.88 (0.81– 0.95)

Every 5 years of treatment era: 12% lower mortality rate

No adjustment for therapy



> Acute Lymphoblastic Leukemia

No adjustment for therapy 0.88 (0.81– 0.95) Adjustment for therapy 1.02 (0.83–1.24)†

† Data were adjusted for cranial radiotherapy dose, anthracycline dose, and exposure to epipodophyllotoxins and glucocorticoids.



Publications 274

Communication

Childhood Cancer Survivorship Research in Minority Populations: A Position Paper From the Childhood Cancer Survivor Study

Smita Bhatia, MD, MPH¹; Todd M. Gibson, PhD²; Kirsten K. Ness, PhD²; Qi Liu, MS³; Kevin C. Oeffinger, MD^{4,5}; Kevin R. Krull, PhD²; Paul C. Nathan, MD, MSc⁶; Joseph P. Neglia, MD, MPH⁷; Wendy Leisenring, ScD⁸; Yutaka Yasui, PhD^{2,3}; Leslie L. Robison, PhD²; and Gregory T. Armstrong, MD, MSCE²



Publications 268

VOLUME 34 · NUMBER 14 · MAY 10, 2016	
JOURNAL OF CLINICAL ONCOLOGY	ORIGINAL REPORT

Racial/Ethnic Differences in Adverse Outcomes Among Childhood Cancer Survivors: The Childhood Cancer Survivor Study

Qi Liu, Wendy M. Leisenring, Kirsten K. Ness, Leslie L. Robison, Gregory T. Armstrong, Yutaka Yasui, and Smita Bhatia

	Hispanic vs. NHW	African American vs. NHW
Socioeconomic status Annual household income <20,000 Education <high school<br="">With health insurance</high>		3.5 (3.1–3.9); <i>P</i> <.001 1.5 (1.3–1.7); <i>P</i> <.001 0.7 (0.6- 0.8); <i>P</i> <.001
		0.5 (0.5–0.6); <i>P</i> <.001 0.5 (0.5–0.6); <i>P</i> = .001

1.6 (1.3–2.0); P<.001


	Hispanic vs. NHW	African American vs. NHW
Socioeconomic status Annual household income <20,000 Education <high school<br="">With health insurance</high>	1.6 (1.5–1.8); <i>P</i> <.001 1.3 (1.1–1.5); <i>P</i> <.001 0.5 (0.5–0.6); <i>P</i> <.001	3.5 (3.1–3.9); <i>P<</i> .001 1.5 (1.3–1.7); <i>P<</i> .001 0.7 (0.6- 0.8); <i>P<</i> .001
Risky health behaviors Current smokers Alcohol consumption (binge drinking) Physically inactive ^b	0.6 (0.6–0.8); <i>P</i> <.001 1.1 (1.0–1.2); <i>P</i> = .07 1.0 (0.8–1.2); <i>P</i> = .8	0.5 (0.5–0.6); <i>P</i> <.001 0.5 (0.5–0.6); <i>P</i> = .001 1.6 (1.3–2.0); <i>P</i> <.001

	Hispanic vs. NHW	African American vs. NHW	
Socioeconomic status Annual household income <20,000 Education <high school<br="">With health insurance Risky health behaviors Current smokers Alcohol consumption (binge drinking) Physically inactive^b</high>	1.6 (1.5–1.8); P <.001 1.3 (1.1–1.5); P <.001 0.5 (0.5–0.6); P <.001 0.6 (0.6–0.8); P <.001 1.1 (1.0–1.2); P = .07 1.0 (0.8–1.2); P = .8	3.5 (3.1–3.9); <i>P</i> <.001 1.5 (1.3–1.7); <i>P</i> <.001 0.7 (0.6- 0.8); <i>P</i> <.001 0.5 (0.5–0.6); <i>P</i> <.001 0.5 (0.5–0.6); <i>P</i> = .001 1.6 (1.3–2.0); <i>P</i> <.001	
Obesity Hypertension Diabetes	1.6 (1.4–1.7); <i>P</i> <.001 1.1 (0.9–1.2); <i>P</i> = .3 1.7 (1.4–2.1); <i>P</i> <.001 1.4 (1.1–1.8); <i>P</i> = .003	1.6 (1.4–1.8); <i>P</i> p<.001 1.3 (1.2–1.5); <i>P</i> <.001 2.3 (1.9–2.9); <i>P</i> <.001 1.9 (1.5–2.3); <i>P</i> <.001	
	0.9 (0.6–1.3); <i>P</i> = .6 0.8 (0.5–1.1); <i>P</i> = .2	1.9 (1.4–2.5); <i>P</i> <.01 1.5 (1.1–2.0); <i>P</i> = .01	


	Hispanic vs. NHW	African American vs. NHW
Socioeconomic status Annual household income <20,000 Education <high school<br="">With health insurance Risky health behaviors Current smokers Alcohol consumption (binge drinking) Physically inactive^b</high>	1.6 (1.5–1.8); P <.001 1.3 (1.1–1.5); P <.001 0.5 (0.5–0.6); P <.001 0.6 (0.6–0.8); P <.001 1.1 (1.0–1.2); P = .07 1.0 (0.8–1.2); P = .8	3.5 (3.1–3.9); <i>P</i> <.001 1.5 (1.3–1.7); <i>P</i> <.001 0.7 (0.6- 0.8); <i>P</i> <.001 0.5 (0.5–0.6); <i>P</i> <.001 0.5 (0.5–0.6); <i>P</i> = .001 1.6 (1.3–2.0); <i>P</i> <.001
Obesity Hypertension Diabetes Diabetes ^c	1.6 (1.4–1.7); P <.001 1.1 (0.9–1.2); P = .3 1.7 (1.4–2.1); P <.001 1.4 (1.1–1.8); P = .003 0.9 (0.6–1.3); P = .6 0.8 (0.5–1.1); P = .2	1.6 (1.4–1.8); <i>P</i> p<.001 1.3 (1.2–1.5); <i>P</i> <.001 2.3 (1.9–2.9); <i>P</i> <.001 1.9 (1.5–2.3); <i>P</i> <.001 1.9 (1.4–2.5); <i>P</i> <.01 1.5 (1.1–2.0); <i>P</i> = .01


	Hispanic vs. NHW	African American vs. NHW
Socioeconomic status Annual household income <20,000 Education <high school<br="">With health insurance Risky health behaviors Current smokers Alcohol consumption (binge drinking) Physically inactive^b</high>	1.6 (1.5–1.8); P <.001 1.3 (1.1–1.5); P <.001 0.5 (0.5–0.6); P <.001 0.6 (0.6–0.8); P <.001 1.1 (1.0–1.2); P = .07 1.0 (0.8–1.2); P = .8	3.5 (3.1–3.9); <i>P</i> <.001 1.5 (1.3–1.7); <i>P</i> <.001 0.7 (0.6- 0.8); <i>P</i> <.001 0.5 (0.5–0.6); <i>P</i> <.001 0.5 (0.5–0.6); <i>P</i> = .001 1.6 (1.3–2.0); <i>P</i> <.001
Obesity Hypertension Diabetes Diabetes ^c	1.6 (1.4–1.7); <i>P</i> <.001 1.1 (0.9–1.2); <i>P</i> = .3 1.7 (1.4–2.1); <i>P</i> <.001 1.4 (1.1–1.8); <i>P</i> = .003	1.6 (1.4–1.8); <i>P</i> p<.001 1.3 (1.2–1.5); <i>P</i> <.001 2.3 (1.9–2.9); <i>P</i> <.001 1.9 (1.5–2.3); <i>P</i> <.001
Stroke ^c	0.9 (0.6–1.3); <i>P</i> = .6 0.8 (0.5–1.1); <i>P</i> = .2	1.9 (1.4–2.5); <i>P</i> <.01 1.5 (1.1–2.0); <i>P</i> = .01

Cumulative cause-specific mortality




Cumulative cause-specific mortality





- By and large, comparable burden of morbidity and mortality
- A few differences in risk were explained by differences in socioeconomic status




Health care use, adjusted for education, income, and insurance General physical examination Cancer-related care Surveillance for long-term toxicities, adjusted for education, income, and insurance Mammography in women treated with chest irradiation Echocardiogram in anthracycline-exposed survivors

Hispanic
VS.
NHW

1.1 (1.0–1.2); P = .11.0 (0.9–1.1); P = .8

Health care use, adjusted for education, income, and insurance General physical examination Cancer-related care Surveillance for long-term toxicities, adjusted for education, income, and insurance Mammography in women treated with chest irradiation Echocardiogram in anthracycline-exposed survivors





Publications 254

VOLUME 33 · NUMBER 32 · NOVEMBER 10 2015	
JOURNAL OF CLINICAL ONCOLOGY	ORIGINAL REPORT

Equivalence Ratio for Daunorubicin to Doxorubicin in Relation to Late Heart Failure in Survivors of Childhood Cancer

Elizabeth A.M. Feijen, Wendy M. Leisenring, Kayla L. Stratton, Kirsten K. Ness, Helena J.H. van der Pal, Huib N. Caron, Gregory T. Armstrong, Daniel M. Green, Melissa M. Hudson, Kevin C. Oeffinger, Leslie L. Robison, Marilyn Stovall, Leontien C.M. Kremer, and Eric J. Chow



		Table 3.	HRs fo <mark>r He</mark> a	art Failure Based
		Da	aunorubicin	
	Dose,	mg/m ²		
Model and Dose Category	Median	IQR	HR*	95% CI
Primary model*				
None			Reference	
\leq 0.1 to $<$ 200 mg/m ²	100	75-118	1.09	0.57 to 2.08
\leq 200 to $<$ 300 mg/m ²	246	221-27(3.16	1.16 to 8.61
\leq 300 to $<$ 400 mg/m ²	350	328-371	4.33	1.73 to 10.84
\leq 400 mg/m ²	480	432-54	10.72	5.13 to 22.42
Secondary modelt				
None			Reference	
\leq 0.1 to $<$ 150 mg/m ²	99	51-103	1.35	0.18 to 10.42
\leq 150 to $<$ 300 mg/m ²	213	183-251	2.83	0.37 to 21.57
\leq 300 mg/m ²	379	346-449	20.17	8.83 to 46.06

Abbreviations: HR, hazard ratio; IQR, interquartile range.

*Model was adjusted for sex; age at diagnosis; chest radiotherapy dose; and exposure to another anthracycline besides doxorubicin or daunorubicin, such as epirubicin, idarubicin, or mitoxantrone. It was also stratified by cohort.

†Model was adjusted for sex and age at diagnosis and was also stratified by cohort.

‡The Cls of the ratios are the 2.5th and 97.5th percentiles of the bootstraps.



Table 3. HRs for Heart Failure Based on Doxorubicin and Daunorubicin Dose Cat								ubicin Dose Cate
	Daunorubicin					[Doxorubicin	
Madal and Daga	Dose,	mg/m ²			Dose,	mg/m ²		
Model and Dose Category	Median	IQR	HR*	95% CI	Median	IQR	HR	95% CI
Primary model*								
None			Reference				Reference	
\leq 0.1 to $<$ 200 mg/m ²	100	75-118	1.09	0.57 to 2.08	122	80-169	2.80	1.75 to 4.49
\leq 200 to $<$ 300 mg/m ²	246	221-27	3.16	1.16 to 8.61	253	226-278	6.31	4.11 to 9.69
\leq 300 to < 400 mg/m ²	350	328-37	4.33	1.73 to 10.84	347	318-370	13.19	9.04 to 19.25
\leq 400 mg/m ²	480	432-54	10.72	5.13 to 22.42	459	430-50	18.43	12.82 to 26.50
Secondary modelt								
None			Reference				Reference	
\leq 0.1 to $<$ 150 mg/m ²	99	51-103	1.35	0.18 to 10.42	102	71-122	3.97	1.14 to 13.76
\leq 150 to $<$ 300 mg/m ²	213	183-251	2.83	0.37 to 21.57	211	180-258	9.29	4.58 to 18.86
\leq 300 mg/m ²	379	346-449	20.17	8.83 to 46.06	391	345-455	34.74	19.24 to 62.73

Abbreviations: HR, hazard ratio; IQR, interquartile range.

*Model was adjusted for sex; age at diagnosis; chest radiotherapy dose; and exposure to another anthracycline besides doxorubicin or daunorubicin, such as epirubicin, idarubicin, or mitoxantrone. It was also stratified by cohort.

†Model was adjusted for sex and age at diagnosis and was also stratified by cohort.

‡The CIs of the ratios are the 2.5th and 97.5th percentiles of the bootstraps.



Childhood Cancer Survivor Study **Epidemiology/Biostatistics Working Group**

Table 3. HRs for Heart Failure Based on Doxorubicin and Daunorubicin Dose Categories												
		D	aunorubicin			Doxorubicin						
Model and Dose	Dose, mg/m ²			Dose, mg/m²					Daunorubicin-to-Doxorubicin Ratio			
Category	Median	IQR	HR*	95% CI	Median	IQR	HR	95% CI	Ratio	95% CI	Mean	95% CI
Primary model* None			Reference				Reference		_		0.45	0.23 to 0.73
\leq 0.1 to < 200 mg/m ²	100	75-118		0.57 to 2.08	122	80-169	2.80	1.75 to 4.49	0.39	0.04 to 0.78		
\leq 200 to < 300 mg/m ²	246	221-27(3.16	1.16 to 8.61	253	226-278	6.31	4.11 to 9.69	0.50	0.00 to 1.12		
\leq 300 to < 400 mg/m ²	350	328-37	4.33	1.73 to 10.84	347	318-370	13.19	9.04 to 19.25	0.33	0.03 to 0.62		
\leq 400 mg/m ²	480	432-54	10.72	5.13 to 22.42	459	430-50	18.43	12.82 to 26.50	0.58	0.09 to 1.12		
Secondary model†											0.41	0.29 to 1.28‡
None			Reference				Reference		—			
\leq 0.1 to < 150 mg/m ²	99	51-103	1.35	0.18 to 10.42	102	71-122	3.97	1.14 to 13.76	0.34	0.14 to 2.60‡		
\leq												
Abb Dar	1004	hi			004	diat		han de		mhiai	b •	
	mor	upi	CIII Wa	as iess	car	uiot	UXIC T	han do	DXU	rupicii	11;	ch as
the daunorubicin-to-doxorubicin cardiotoxicity equivalence												

ratio was between 0.4 and 0.5.



Publications 293

Research Article



Received 22 January 2016, Accepted 12 December 2016

Published online 18 January 2017 in Wiley Online Library

(wileyonlinelibrary.com) DOI: 10.1002/sim.7217

Regression analysis of mixed panel count data with dependent terminal events

Guanglei Yu,^a Liang Zhu,^b Yang Li,^c Jianguo Sun^{a*†}[©] and Leslie L. Robison^d

$$\hat{\mu}_0(t;\boldsymbol{\beta},\hat{\boldsymbol{\omega}}(t)) = \frac{\sum_{i=1}^n r_i(t)\hat{\omega}_i(t)\tilde{N}_i(t)}{n\tilde{S}_r^{(0)}(t;\boldsymbol{\beta},\hat{\boldsymbol{\omega}}(t))}$$

and

$$\hat{\mu}_0(t;\beta,\hat{\boldsymbol{\omega}}(t))\,d\hat{\Gamma}_0(t;\beta,\hat{\boldsymbol{\omega}}(t)) = \frac{\sum_{i=1}^n (1-r_i(t))\tilde{N}_i(t)d\tilde{O}_i(t)}{n\tilde{S}_p^{(0)}(t;\beta,\hat{\boldsymbol{\omega}}(t))}\,,$$

where

$$\tilde{S}_{r}^{(d)}(t;\beta,\hat{\boldsymbol{\omega}}(t)) = \frac{1}{n} \sum_{i=1}^{n} r_{i}(t)\hat{\omega}_{i}(t) \exp\{\beta^{T} Z_{i}\} Z_{i}^{\bigotimes d},$$

$$\tilde{S}_{p}^{(d)}(t;\beta,\hat{\boldsymbol{\omega}}(t)) = \frac{1}{n} \sum_{i=1}^{n} (1 - r_{i}(t))\hat{\omega}_{i}(t) \exp\{\beta^{T} Z_{i}\} Z_{i}^{\bigotimes d}, d = 0, 1, 2,$$

 $\mathbf{a}^{\otimes 0} = 1, \mathbf{a}^{\otimes 1} = \mathbf{a}, \mathbf{a}^{\otimes 2} = \mathbf{a}\mathbf{a}'$, and $\boldsymbol{\omega}(t) = (\omega_1(t), \dots, \omega_n(t))'$. By plugging the two estimators earlier into Equation (5), we obtain

$$U(\beta) = \sum_{i=1}^{n} \int_{0}^{\tau} r_{i}(t)\hat{\omega}_{i}(t)(Z_{i} - \bar{Z}_{r}(t;\beta,\hat{\omega}(t)))\tilde{N}_{i}(t)dH(t) + (1 - r_{i}(t))(Z_{i} - \bar{Z}_{p}(t;\beta,\hat{\omega}(t)))\tilde{N}_{i}(t)d\tilde{O}_{i}(t) = 0,$$
(6)

where $\bar{Z}_r(t; \beta, \hat{\omega}(t)) = \tilde{S}_r^{(1)}(t; \beta, \hat{\omega}(t)) / \tilde{S}_r^{(0)}(t; \beta, \hat{\omega}(t))$ and $\bar{Z}_p(t; \beta, \hat{\omega}(t)) = \tilde{S}_p^{(1)}(t; \beta, \hat{\omega}(t)) / \tilde{S}_p^{(0)}(t; \beta, \hat{\omega}(t))$.

Let $\hat{\beta}$ denote the estimator of β_0 given by solving Equation (6). To establish the asymptotic properties of $\hat{\beta}$, define $N_i^d(t) = I(D_i \leq t, D_i \leq C_i)$,

$$M_i^d(t;\delta) = N_i^d(t) - \int_0^t I(T_i^* \ge s) \exp\{\delta^T Z_i\} d\Delta_0(s),$$

and $\bar{Z}_d(t;\hat{\delta}) = \tilde{S}_d^{(1)}(t;\hat{\delta}) / \tilde{S}_d^{(0)}(t;\hat{\delta})$, where $\Delta_0(t) = \int_0^t \lambda_0^d(s) ds$ and

$$\tilde{S}_{d}^{(d)}(t;\delta) = \frac{1}{n} \sum_{i=1}^{n} I(T_{i}^{*} \ge t) \exp\{\delta^{T} Z_{i}\} Z_{i}^{\bigotimes d}, d = 0, 1, 2.$$



Publications 293

- Regression analysis methodology
- Recurrent event data (e.g., BCC, pregnancy)
 +
- Panel count data: observed at discrete time points




Submitted manuscript 1

Where, When, and Why Adult Survivors of Childhood Cancer Seek Internet-based Health Information

Mechelle D Claridy¹, Melissa M Hudson^{2, 3}, Jeanne Steele⁴, Lee Caplan¹, Pauline A Mitby⁵, Wendy Leisenring⁶, Selina A Smith⁷, Leslie L Robison², Ann C Mertens⁸







In the past 12 months, have you looked for		CCSS		HINTS	
health or medical information for yourself		(n=1386)		(n=2385)	
while using the internet?		OR (95% CI)		R (95% CI)	
Overall		2.76 (2.40-3	3.19)	1.0	
How much do you trust information about health or medical topics from sources listed below?		Doctor or Healthcare Professional			
sources listed below?	CCSS Mean (SD)		*p-value	_	
Total	3.77 (0.50)	3.63 (0.62)	< 0.01		



Submitted manuscript 2

Yuan Y, Zhou QM, Li B, Cai H, Chow EJ, Armstrong GT.

A Threshold-free Prospective Prediction Accuracy Measure for Censored Time to Event Data

(invited for revision by Statistics in Medicine)



1. Scope of your Working Group

2. Publications since the 2015 mtg

3. Ongoing work

4. Future focus



Di / Wendy Inverse Prob Weighting

- Address bias concern due to nonparticipation (FU Survey 5)
- Inverse Probability Weighting (IPW) to boost contribution for survivors with characteristics of low participation
- Methodological paper that describes the application of IPW in CCSS



- Tiled study design: using temporal overlap as a method to extend longitudinal follow-up among carefully selected time-limited cohorts (Chow)
- Use of an incentive to increase biologic sample (Oragene) return rate (McDonald)
- Radiation dose reconstruction methods for intensity modulated radiation therapy (Howell)
- Handling Missing Data due to No Consent for Medical Record Abstraction by Multiple Imputation (Martin/Liu)



Funded Ancillary Projects

Principal Investigator: Liang Zhu (St. Jude Children's Research Hosp Title: New Methods to Address Dilemmas in Mixed Recurrent-event and Dates of Funding: 7/16 - 6/18 Funding Source: National Institutes of Health (R21) Award: \$501,312 Study Aims: To develop semi-parametric methods for regression analyse event and compare them with alternative methods by simulation studies

Principal Investigator: Yan Yuan (University of Alberta) Title: Risk Prediction Model of Premature Menopause in Childhood Cance Dates of Funding: 7/16 - 12/18 Funding Source: Canadian Institutes of Health Research Award: \$179,858 Study Aims: To develop a prediction model for early menopause



Childhood Cancer Survivor Study

Epidemiology/Biostatistics Working Group

Principal Investigator: Lennie Wong (City of Hope) Title: Cost effectiveness of breast cancer screening guidelines for female sur Dates of Funding: 7/17 - 6/20 Funding Source: American Cancer Society Award: \$527,000 Study Aims: 1) Examine the cost-effectiveness of 1) annual clinical breast ex vs. MRI as adjunct to mammography.

Principal Investigator: Yutaka Yasui, Jinghui Zhang (St. Jude Children's Reseat Title: Late Effects Prediction using Clinical Phenotypes and Whole Genome Sequences of Funding: 4/17 - 3/22
Funding Source: National Institutes of Health, RO1
Award: \$3,457,455
Study Aims: 1) Build individual risk prediction models with the SJLIFE cohort for basal cell carcinoma, and multiple subsequent neoplasms, 2) Validate the risk prediction for higher SN counts (CCSS)



Submitted Ancillary Projects

Principal Investigator: Liang Zhu (University of Texas MD Anderson) Title: Statistical Analysis for Mixed Outcome Measures in Recurrent Event Proposed Funding Source: American Cancer Society Study Aims: Develop a likelihood-based semiparametric estimation metho and panel-count data.

Status: Submitted October 2016, scored 20, awaiting funding decision



1. Scope of your Working Group

2. Publications since the 2015 mtg

3. Ongoing work

4. Future focus

- Temporal trends
- Prediction modeling and model evaluation
- Cost-effectiveness analysis
- GWAS analysis

G x Tx interaction / Tx-stratified analysis

Alternative analytic methodologies



Working Group => Your entry to CCSS

PLEASE CONTACT ME IF YOU HAVE ANY INTEREST OR IDEA ON POTENTIAL EPI/BIOSTAT PROJECTS

Yutaka.Yasui@stjude.org